Scientists create first new antibiotic in nearly three decades

Scientists create first new antibiotic in nearly three decades

5:07 AM, 9th January 2015
Scientists create first new antibiotic in nearly three decades
Antibiotics have been the magic bullets for human health for decades but irrational use and mindless popping has made majority of the world’s bugs resistant to them.

LONDON, UK: In a massive breakthrough, scientists have created the first new antibiotic in more than three decades, Teixobactin, that can treat many common bacterial infections such as tuberculosis, septicemia and C Diff or clostridium difficile colitis.

The discovery comes at a time when World Health Organization has sent out warnings that humanity is staring at a post-antibiotic era when common infections will no longer have a cure. The first antibiotic, Penicillin, was discovered by Alexander Fleming in 1928, and more than 100 compounds have been found since then, but no new class has been found since 1987.

Antibiotics have been magic bullets for human health for decades but irrational use has made most bugs resistant to these. Kim Lewis, Professor, Northeastern University announced the discovery of the antibiotic that eliminates pathogens without encountering any detectable resistance. Lewis and Northeastern biology professor Slava Epstein co?authored the finding with colleagues from the University of Bonn in Germany, Novo Biotic Pharmaceuticals in Cambridge, Massachusetts, and Selcia Ltd in the United Kingdom.

Most antibiotics target bacterial proteins, but bugs can become resistant by evolving new kinds of proteins. What’s unique about Teixobactin is that it launches a double attack on the building blocks of bacterial cell walls. Experts say this will pave the way for a new generation of antibiotics because of the way it was discovered.

Teixobactin could be available in the next five years. Its testing on mice has shown it clears infections without side-effects. The NU team led by Prof Lewis is now concentrating on upscaling production of Teixobactin to test it on humans.

Northeastern researchers’ pioneering work to develop a novel method for growing uncultured bacteria led to the discovery of the antibiotic, and Lewis’s lab played a key role in analyzing and testing the compound for resistance from pathogens. Lewis said this marks the first discovery of an antibiotic to which resistance by mutations of pathogens have not been identified.

“So far, the strategy has been based on developing new antibiotics faster than the pathogens acquire resistance. Teixobactin presents a new opportunity to develop compounds that are essentially free of resistance,” said Lewis.

The screening of soil micro-organisms has produced most antibiotics, but only one per cent of these will grow in the lab, explained Lewis. He and Epstein spent years seeking to address this problem by tapping into a new source of antibiotics beyond those created by synthetic means: uncultured bacteria, which make up 99 per cent of all species in external environments.

They developed a novel method for growing uncultured bacteria in their natural environment. Their approach involves the iChip, a miniature device Epstein’s team created that can isolate and help grow single cells in their natural environment and provide researchers with much improved access to uncultured bacteria.

“Novo Biotic has assembled about 50,000 strains of uncultured bacteria and discovered 25 new antibiotics, of which Teixobactin is the latest and most interesting. Our impression is that nature produced a compound that evolved to be free of resistance. This challenges the dogma that we’ve operated under that bacteria will always develop resistance. Well, maybe not in this case,” said Lewis.

© TimesOfIndia News 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Air Products reports higher volumes, but diluted earnings per share

Record EPS from continuing operations of $1.46 Sales of $2.6 billion, up 14 per cent versus prior year Fourth quarter EPS expected to be $1.48 to ...

Read more
DuPont acquires Innovalight for solar energy market

DELAWARE, US: DuPont acquired Innovalight Inc, a company specializing in advanced silicon inks and process technologies that increase the efficiency o ...

Read more
Dow, Saudi Aramco JV to build chemicals complex in Saudi Arabia

  MIDLAND, US/DHAHRAN, SAUDI ARABIA: The Dow Chemical Company and Saudi Aramco have formed a joint venture to build and operate a world-scale, f ...

Read more
Solutia plans PVB resin plant at Kuantan, Malaysia facility

  ST LOUIS, US: Solutia Inc will expand its Kuantan, Malaysia facility by adding a polyvinyl butyral interlayers (PVB) resin plant at the site. ...

Read more
Merck, Nano-C to jointly develop new materials for OPV applications

  DARMSTADT, GERMANY: Merck KGaA has signed a collaboration agreement with Nano-C Inc (Westwood, US). Both companies will jointly develop and co ...

Read more
Solutia posts positive results, maintains guidance outlook

  Net sales of $543 million; an 8 per cent increase from the same period in 2010. Diluted earnings per share from continuing operations of $0 ...

Read more